P-0


| Title | ADC(항체-약물 접합체) 혁신기술소개 |
|---|---|
| Date | 2026.08.25 (10:25 - 10:40) | The Platz Hall Seminar Room |
| Organization | Cyron Therapeutics |
| Speaker | Sangsoon Yoon, CEO |
Conditionally activated anti-CD155 Ab-drug conjugates development
[Brief Introduction of Speaker]
After majoring in immunology, Dr. Yoon led the full development cycle—from antibody discovery to Phase 1 clinical trials—at an antibody development company. As the founder of Cyron Therapeutics, he is currently developing a trispecific T-cell engagers platform and bispecific antibody-drug conjugates (ADCs), among other projects.